{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:07:58Z","timestamp":1787058478413,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ijcard.2022.01.060","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T11:08:47Z","timestamp":1643627327000},"page":"96-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Ticagrelor for prevention of stroke and cognitive impairment in patients with vascular high-risk factors: A meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"353","author":[{"given":"Xiaohui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zetian","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2022.01.060_bb0005","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","article-title":"Global, regional, and national age-sex specific mortality for 264 causes of death, 1980\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","year":"2017","journal-title":"Lancet"},{"issue":"229\u201338","key":"10.1016\/j.ijcard.2022.01.060_bb0010","first-page":"e13","article-title":"Post-stroke cognitive decline: an update and perspectives for clinical research","volume":"22","author":"Brainin","year":"2015","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0015","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(18)30802-X","article-title":"Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study","volume":"391","author":"Langhorne","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2022.01.060_bb0020","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0025","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4244\/EIJV9I3A53","article-title":"The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation","volume":"9","author":"Liang","year":"2013","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ijcard.2022.01.060_bb0030","article-title":"Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial","volume":"365","author":"Wang","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2022.01.060_bb0035","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1161\/STROKEAHA.120.032670","article-title":"Network meta-analysis of ticagrelor for stroke prevention in patients at high risk for cardiovascular or cerebrovascular events","volume":"52","author":"B\u00e1lint","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2022.01.060_bb0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA","volume":"383","author":"Johnston","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0045","series-title":"Brilinta Approved in the US to Reduce the Risk of Stroke in Patients With an Acute Ischaemic Stroke or High-risk Transient Ischaemic Attack","author":"Kemp","year":"2020"},{"key":"10.1016\/j.ijcard.2022.01.060_bb0050","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.110.985325","article-title":"Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor","volume":"123","author":"Gaglia","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2022.01.060_bb0055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease","volume":"376","author":"Hiatt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0060","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1603060","article-title":"Ticagrelor versus aspirin in acute stroke or transient ischemic attack","volume":"375","author":"Johnston","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0065","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0070","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"key":"10.1016\/j.ijcard.2022.01.060_bb0075","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/bimj.201600034","article-title":"Performance of the Peto odds ratio compared to the usual odds ratio estimator in the case of rare events","volume":"58","author":"Brockhaus","year":"2016","journal-title":"Biom. J."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0080","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0085","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0140-6736(20)32236-4","article-title":"Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial","volume":"396","author":"Silvain","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2022.01.060_bb0090","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jacc.2007.07.053","volume":"50","author":"Cannon","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0095","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0100","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1253\/circj.CJ-15-0112","article-title":"Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome \u2014 randomized, double-blind, phase III PHILO study","volume":"79","author":"Goto","year":"2015","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0105","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/FJC.0000000000000390","article-title":"Assessment of ticagrelor versus clopidogrel treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"68","author":"Tang","year":"2016","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0110","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamacardio.2018.0612","article-title":"Ticagrelor vs clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a randomized clinical trial","volume":"3","author":"Berwanger","year":"2018","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0115","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.jacc.2014.03.031","article-title":"Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance","volume":"63","author":"Cattaneo","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0120","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/CIRCULATIONAHA.109.919456","article-title":"Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study","volume":"121","author":"Gurbel","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2022.01.060_bb0125","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jcin.2016.02.039","article-title":"Pharmacodynamic effects of switching from prasugrel to ticagrelor: results of the prospective, randomized SWAP-3 study","volume":"9","author":"Franchi","year":"2016","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0130","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s00415-019-09630-4","article-title":"Post-stroke cognitive impairment as an independent predictor of ischemic stroke recurrence: PICASSO sub-study","volume":"267","author":"Kwon","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13024-020-00421-4","article-title":"Increased serum QUIN\/KYNA is a reliable biomarker of post-stroke cognitive decline","volume":"16","author":"Cogo","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0140","doi-asserted-by":"crossref","first-page":"12088","DOI":"10.1038\/s41598-017-12205-w","article-title":"Effects of ticagrelor in a mouse model of ischemic stroke","volume":"7","author":"Yamauchi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0145","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.brainres.2016.10.017","article-title":"Neuroprotection of Cilostazol against ischemia\/reperfusion-induced cognitive deficits through inhibiting JNK3\/caspase-3 by enhancing Akt1","volume":"1653","author":"Qi","year":"2016","journal-title":"Brain Res."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0150","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0155","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S1474-4422(14)70224-8","article-title":"Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial","volume":"13","author":"Pearce","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0160","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/jce.12776","article-title":"Percent time with a supratherapeutic INR in atrial fibrillation patients also using an antiplatelet agent is associated with long-term risk of dementia","volume":"26","author":"Jacobs","year":"2015","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0165","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1111\/bph.14618","article-title":"Microglial inflammation and phagocytosis in Alzheimer\u2019s disease: potential therapeutic targets","volume":"176","author":"Nizami","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2019.100966","article-title":"Is Alzheimer\u2019s disease an inflammasomopathy?","volume":"56","author":"Pereira","year":"2019","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.ijcard.2022.01.060_bb0175","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/s41423-020-0444-5","article-title":"Ticagrelor inhibits the NLRP3 inflammasome to protect against inflammatory disease independent of the P2Y(12) signaling pathway","volume":"18","author":"Huang","year":"2021","journal-title":"Cell Mol. Immunol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527322001863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527322001863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:56:59Z","timestamp":1759093019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527322001863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":35,"alternative-id":["S0167527322001863"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2022.01.060","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ticagrelor for prevention of stroke and cognitive impairment in patients with vascular high-risk factors: A meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2022.01.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}